IRIS Accounts Production v24.3.0.553 07254808 director 1.2.23 31.1.24 31.1.24 false true false false false true false Ordinary 1.00000 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh072548082023-01-31072548082024-01-31072548082023-02-012024-01-31072548082022-01-31072548082022-02-012023-01-31072548082023-01-3107254808ns15:EnglandWales2023-02-012024-01-3107254808ns14:PoundSterling2023-02-012024-01-3107254808ns10:Director12023-02-012024-01-3107254808ns10:PrivateLimitedCompanyLtd2023-02-012024-01-3107254808ns10:SmallEntities2023-02-012024-01-3107254808ns10:AuditExempt-NoAccountantsReport2023-02-012024-01-3107254808ns10:SmallCompaniesRegimeForDirectorsReport2023-02-012024-01-3107254808ns10:SmallCompaniesRegimeForAccounts2023-02-012024-01-3107254808ns10:FullAccounts2023-02-012024-01-310725480812023-02-012024-01-3107254808ns10:OrdinaryShareClass12023-02-012024-01-3107254808ns10:CompanySecretary12023-02-012024-01-3107254808ns10:RegisteredOffice2023-02-012024-01-3107254808ns5:CurrentFinancialInstruments2024-01-3107254808ns5:CurrentFinancialInstruments2023-01-3107254808ns5:Non-currentFinancialInstruments2024-01-3107254808ns5:Non-currentFinancialInstruments2023-01-3107254808ns5:ShareCapital2024-01-3107254808ns5:ShareCapital2023-01-3107254808ns5:RetainedEarningsAccumulatedLosses2024-01-3107254808ns5:RetainedEarningsAccumulatedLosses2023-01-3107254808ns5:NetGoodwill2023-02-012024-01-3107254808ns5:IntangibleAssetsOtherThanGoodwill2023-02-012024-01-3107254808ns5:FurnitureFittings2023-02-012024-01-3107254808ns5:MotorVehicles2023-02-012024-01-3107254808ns5:ComputerEquipment2023-02-012024-01-3107254808ns5:NetGoodwill2023-01-3107254808ns5:NetGoodwill2024-01-3107254808ns5:NetGoodwill2023-01-3107254808ns5:FurnitureFittings2023-01-3107254808ns5:MotorVehicles2023-01-3107254808ns5:ComputerEquipment2023-01-3107254808ns5:FurnitureFittings2024-01-3107254808ns5:MotorVehicles2024-01-3107254808ns5:ComputerEquipment2024-01-3107254808ns5:FurnitureFittings2023-01-3107254808ns5:MotorVehicles2023-01-3107254808ns5:ComputerEquipment2023-01-3107254808ns5:CurrentFinancialInstrumentsns5:WithinOneYear2024-01-3107254808ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-01-3107254808ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2024-01-3107254808ns5:Non-currentFinancialInstrumentsns5:BetweenOneTwoYears2023-01-3107254808ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2024-01-3107254808ns5:Non-currentFinancialInstrumentsns5:BetweenTwoFiveYears2023-01-3107254808ns10:OrdinaryShareClass12024-01-3107254808ns5:RetainedEarningsAccumulatedLosses2023-01-3107254808ns5:RetainedEarningsAccumulatedLosses2023-02-012024-01-31
REGISTERED NUMBER: 07254808 (England and Wales)















Unaudited Financial Statements for the Year Ended 31 January 2024

for

Naspram Pharma Limited

Naspram Pharma Limited (Registered number: 07254808)






Contents of the Financial Statements
for the Year Ended 31 January 2024




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Naspram Pharma Limited

Company Information
for the Year Ended 31 January 2024







DIRECTOR: Mr S Patel





SECRETARY: Mrs A Patel





REGISTERED OFFICE: 110 Carlton Avenue East
Wembley
Middlesex
HA9 8LY





REGISTERED NUMBER: 07254808 (England and Wales)





ACCOUNTANTS: MohanRed & Co
110 Carlton Avenue East
Wembley
Middlesex
HA9 8LY

Naspram Pharma Limited (Registered number: 07254808)

Balance Sheet
31 January 2024

31.1.24 31.1.23
Notes £    £    £    £   
FIXED ASSETS
Intangible assets 4 - -
Tangible assets 5 118,958 111,023
118,958 111,023

CURRENT ASSETS
Stocks 49,260 52,850
Debtors 6 1,361,417 420,454
Cash at bank 880,276 771,991
2,290,953 1,245,295
CREDITORS
Amounts falling due within one year 7 968,271 762,502
NET CURRENT ASSETS 1,322,682 482,793
TOTAL ASSETS LESS CURRENT
LIABILITIES

1,441,640

593,816

CREDITORS
Amounts falling due after more than one
year

8

976,802

72,077
NET ASSETS 464,838 521,739

CAPITAL AND RESERVES
Called up share capital 9 100 100
Retained earnings 10 464,738 521,639
SHAREHOLDERS' FUNDS 464,838 521,739

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 January 2024.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 January 2024 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Naspram Pharma Limited (Registered number: 07254808)

Balance Sheet - continued
31 January 2024


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 25 October 2024 and were signed by:





Mr S Patel - Director


Naspram Pharma Limited (Registered number: 07254808)

Notes to the Financial Statements
for the Year Ended 31 January 2024

1. STATUTORY INFORMATION

Naspram Pharma Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Goodwill
Goodwill, being the amount paid in connection with the acquisition of a business in 2011, is being amortised evenly over its estimated useful life of four years.

Intangible assets
Intangible assets are initially measured at cost. After initial recognition, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Fixtures and fittings - 25% on reducing balance
Motor vehicles - 25% on reducing balance
Computer equipment - 25% on reducing balance

Stocks
Stocks are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.


Naspram Pharma Limited (Registered number: 07254808)

Notes to the Financial Statements - continued
for the Year Ended 31 January 2024

2. ACCOUNTING POLICIES - continued
Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 5 (2023 - 6 ) .

4. INTANGIBLE FIXED ASSETS
Goodwill
£   
COST
At 1 February 2023
and 31 January 2024 244,500
AMORTISATION
At 1 February 2023
and 31 January 2024 244,500
NET BOOK VALUE
At 31 January 2024 -
At 31 January 2023 -

Naspram Pharma Limited (Registered number: 07254808)

Notes to the Financial Statements - continued
for the Year Ended 31 January 2024

5. TANGIBLE FIXED ASSETS
Fixtures
and Motor Computer
fittings vehicles equipment Totals
£    £    £    £   
COST
At 1 February 2023 166,788 45,000 33,928 245,716
Additions 17,028 - 20,325 37,353
At 31 January 2024 183,816 45,000 54,253 283,069
DEPRECIATION
At 1 February 2023 87,176 37,722 9,795 134,693
Charge for year 21,566 1,819 6,033 29,418
At 31 January 2024 108,742 39,541 15,828 164,111
NET BOOK VALUE
At 31 January 2024 75,074 5,459 38,425 118,958
At 31 January 2023 79,612 7,278 24,133 111,023

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.1.24 31.1.23
£    £   
Trade debtors - 1,886
Amounts owed by participating interests 1,323,396 395,745
Other debtors 38,021 22,823
1,361,417 420,454

Included within participated undertakings were loans due from PSM Portfolio Limited , Airspins Limited and Central Pharmaclinics Limited.

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
31.1.24 31.1.23
£    £   
Bank loans < 1 year - 21,880
Trade creditors 281,818 245,502
Other creditors 11,479 3,482
Tax 38,447 26,490
Social security and other taxes 3,458 (529 )
Pensions 358 358
Net wages 6,207 (312 )
Directors' current accounts 393,467 248,594
Accruals and deferred income 233,037 217,037
968,271 762,502

Naspram Pharma Limited (Registered number: 07254808)

Notes to the Financial Statements - continued
for the Year Ended 31 January 2024

8. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN
ONE YEAR
31.1.24 31.1.23
£    £   
Bank loan 976,802 -
Bounce back loan - 65,422
Bank loans > 1 year - 6,655
976,802 72,077

9. CALLED UP SHARE CAPITAL

Allotted and issued:
Number: Class: Nominal 31.1.24 31.1.23
value: £    £   
100 Ordinary shares £1 100 100

10. RESERVES
Retained
earnings
£   

At 1 February 2023 521,639
Profit for the year 118,599
Dividends (175,500 )
At 31 January 2024 464,738